Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group - Wikidata - awgldk - TriplyDB

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

http://www.wikidata.org/entity/Q34594224

about

Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma Hematopoietic cell transplantation for B-cell lymphoma: an update Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review Mantle cell lymphoma: observation to transplantation The European Hematology Association Roadmap for European Hematology Research: a consensus document Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from th Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era Mantle cell lymphoma with features of marginal-zone lymphoma.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901

P2860

Q24299054-07F78DEA-10F4-441B-9AC3-E5FA340BDC5B Q24607479-03148B01-F014-4188-B07A-44026A1A73AD Q26738937-CC7FE0C1-ADBC-4A85-AABE-58DAB6C44263 Q26772907-B1E24755-F4EA-482A-ACDB-9D8638547442 Q26783430-DE27444C-A74A-4517-9E21-A7373D2F2E5B Q26998446-03126B6A-7427-4E5B-AE60-812BDF21F807 Q26999011-B80177D3-751E-4A84-8279-80FC01ED32AE Q27026617-708846EE-9C5F-45A2-8877-8B4762CE6693 Q28087748-D021122A-4CA3-49FD-A169-23299AE2E59A Q28256317-45C97756-9D72-4CCF-94DD-21CD49CD3213 Q28830861-2A57111A-1727-4FA3-812E-848EB539C26A Q30358639-BB753DB1-2CB5-438C-ADA4-71D67D1742BA Q30456436-670A6BD6-7A00-4FB5-A428-86051C71A8AA Q30670674-F05B28AD-89CB-4B6D-88A9-1E17A13F0D23 Q33388563-09ECCF89-5251-4D75-B063-2B66FBBAF28D Q33393623-5510C829-644B-4836-B737-13AE522D9C81 Q33394663-777708E4-AC1A-4F35-B33F-2576B6E58776 Q33398818-EE1C3C6F-9378-4D30-88C3-0E1124A70587 Q33399582-6046E047-3337-4A2E-9B3B-1A643789462E Q33408270-D4CABAB6-3D65-40C3-A347-06BD94CEE8CB Q33409261-D9AFE170-1601-4550-B9D1-4C55D256DF31 Q33416695-95A09A72-C061-42DF-8B1A-39E5E88BEFB4 Q33427312-CFDEBCBD-7F48-4F91-A168-38DBD0687B7F Q33585255-3F37100F-04A5-47B3-95F7-2FA517D7123F Q33586239-BD99969A-5927-43FD-99E7-F3674D0AC575 Q33599174-883F3150-B215-4099-9DF8-0108AE5D0691 Q33605275-B3017E2B-663B-4930-84B3-55479C6F16AF Q33800959-A769FDB1-7C20-4C6F-835A-0740CB3C7FAF Q33824082-385E4109-FC51-403A-BA9A-B84EE9E06735 Q33873523-08D1A0C0-5E89-4405-BE46-1F808F6ABB35 Q33909086-089B179E-43A4-4436-A738-BB7E5333A510 Q33917671-9A458DFF-EDD3-49FD-BCBB-60BEE7B49D30 Q34095473-BC3E6B50-79AF-449D-9B8E-7EB5555395D3 Q34129360-C1754CDC-91E7-476A-89C5-536DE30E72C8 Q34231288-B391791F-5FB5-4F2F-A1BE-69A0F5B16567 Q34306214-19B14DE4-894E-48F0-94C7-F8F1CC7E5E03 Q34603567-FED94AF2-A11C-4965-9986-9D386AEF310B Q34803137-093F817B-DD87-450A-A3F8-362F17FA70F8 Q34997715-67EF2CA8-E3DB-43B4-A92A-27879C2B998A Q35100217-4C593611-5D2F-4E40-87A4-22A02D23DC2E

P2860

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

http://www.wikidata.org/entity/Q34594224

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@ast

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@en

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@nl

type

label

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@ast

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@en

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@nl

prefLabel

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@ast

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@en

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@nl

P1433

Q34594224-33697ECD-428B-40B7-9F56-B946818A7AF7

P1476

Q34594224-E39E0FCC-220E-452B-B743-29573FBE17D7

P2093

Q34594224-0DD11B30-B393-406C-8658-16273F670122

Q34594224-144ED534-9C1F-4828-B3A8-1C1B5E484E57

Q34594224-2CC45ED9-BCA1-4256-8D88-15A005D337F3

Q34594224-4F998917-6B52-4A76-8ED7-ED4C7B5CD129

Q34594224-5211DC5C-2C8D-4198-B5A4-937BD09A9DDF

Q34594224-58692F4F-CEF9-4C36-A178-3F8310603603

Q34594224-6B9E7EE4-D922-42CD-B590-4977E6ADDDB1

Q34594224-79169F14-4207-42E4-AB84-E8AC5DBFF4CD

Q34594224-79B245B9-1EC3-438A-A340-8C4CCEC8C371

Q34594224-7BFBE722-4DE2-46EF-9049-D6C12563CB2B

P2860

Q34594224-0B623999-C2B1-4576-9347-6FFC24D28317

Q34594224-0B8DC230-5A9E-4011-883B-C62AA9B9CA7A

Q34594224-155A86E1-4D1E-4DA5-8610-B354E66F19A7

Q34594224-1659859D-65A7-4080-B9D4-A158BC45C8A7

Q34594224-2659B1E7-7755-4594-9BFC-D7093C4EEB1B

Q34594224-281A4C42-87C2-4AD4-9421-14DFE266AC47

Q34594224-2958909E-142B-43F7-8021-16CC89CD9D90

Q34594224-342D5DE1-9FF1-461E-8446-2EFA50B1FAC8

Q34594224-3E503186-84F2-43AB-9AE8-C64D8978518A

Q34594224-5B57E6E8-9567-4805-8966-02F0DD9F5B35

P304

Q34594224-D9CB70BE-C32F-40A8-B166-3120D6594929

P31

Q34594224-641CA3FD-D0E2-4060-812E-21CFEC902523

P356

Q34594224-10A2DD49-6ACE-4FF7-8AD9-8F33BFB67102

P407

Q34594224-4A5D4DD1-0A2E-476E-A6C1-D7E8C8B8DA7D

P433

Q34594224-437D46FD-33F5-49B5-AB47-8EACCD54AA02

P478

Q34594224-622D0C5B-E5B2-40F9-8978-6E6A2E87FB46

P50

Q34594224-07D5F4AC-B709-41F4-9AFD-520155D8BFF1

Q34594224-1BD76C57-607B-4622-B303-56688035124F

Q34594224-7210E968-6D06-4048-997F-00B653A283AD

Q34594224-7D931DDD-0CCA-4C61-821B-AE35A61D3664

Q34594224-809B1E26-CF30-48BF-A1FB-17C2DB6AD77A

Q34594224-B6082842-8137-4F66-87A9-8A16CFEC4F07

P577

Q34594224-BFCCA2C5-319C-4E54-96FC-1DA0925DAA6C

P5875

Q34594224-34D4DCF7-D234-4EF6-BA03-93E358F04776

P698

Q34594224-CC7B636A-D0BD-49CE-BABA-49274BDD682E

P921

Q34594224-B6051A3D-2B18-4F56-877E-923ECCF8D815

P932

Q34594224-81C7AACC-0D44-480C-8343-388BB27D2AD5

P356

BLOOD-2008-03-147025

P1433

P1476

Long-term progression-free sur ...... y by the Nordic Lymphoma Group

@en

P2093

Anna Laurell

http://www.w3.org/2001/XMLSchema#string

Anne Marie Boesen

http://www.w3.org/2001/XMLSchema#string

Arne Kolstad

http://www.w3.org/2001/XMLSchema#string

Christer Sundström

http://www.w3.org/2001/XMLSchema#string

Christian H Geisler

http://www.w3.org/2001/XMLSchema#string

Elisabeth Ralfkiaer

http://www.w3.org/2001/XMLSchema#string

Erkki Elonen

http://www.w3.org/2001/XMLSchema#string

Eva Kimby

http://www.w3.org/2001/XMLSchema#string

Grete F Lauritzsen

http://www.w3.org/2001/XMLSchema#string

Herman Nilsson-Ehle

http://www.w3.org/2001/XMLSchema#string

P2860

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.

Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.

Mantle cell lymphoma-- an entity comes of age.

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.

P304

2687-2693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-03-147025

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth Ralfkiaer

Marja-Liisa Karjalainen-Lindsberg

Herman Nilsson-Ehle

Christian Geisler

P577

2008-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5226262

http://www.w3.org/2001/XMLSchema#string

P698

18625886

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2556606

http://www.w3.org/2001/XMLSchema#string